文献速递免疫规划慢病防控与筛查

随机对照试验的事后分析:糖尿病改变13价肺炎球菌结合疫苗在老年人中的效力

Post-hoc analysis of a randomized controlled trial: Diabetes mellitus modifies the efficacy of the 13-valent pneumococcal conjugate vaccine in elderly.
PubMed 文献 · Vaccine · 2017-04-12

CAPiTA研究的事后分析,纳入84,496名≥65岁免疫功能正常者,接种PCV13或安慰剂。139例发生疫苗型社区获得性肺炎者中,糖尿病显著改变疫苗效力(p=0.002),糖尿病患者VE为89.5%(95%CI 65.5-96.8),无糖尿病者为24.7%(95%CI -10.4至48.7);心脏疾病、呼吸系统疾病、吸烟或任何合并症未见显著效应修饰。

要点

  • 在139例发生疫苗型社区获得性肺炎者中,糖尿病对PCV13效力有显著效应修饰(p=0.002)。
  • 糖尿病患者VE为89.5%(95%CI 65.5-96.8),无糖尿病者为24.7%(95%CI -10.4至48.7)。
  • 心脏疾病、呼吸系统疾病、吸烟或任何合并症未见显著效应修饰。

核心结论

  • 在免疫功能正常的老年人中,PCV13的疫苗效力受糖尿病修饰,糖尿病患者的疫苗效力更高。
  • 心脏疾病、呼吸系统疾病、吸烟或存在任何合并症的受试者中未观察到显著效应修饰。

研究设计与样本

  • CAPiTA研究的事后分析,该研究为双盲随机对照试验,纳入84,496名年龄≥65岁的免疫功能正常参与者,接种PCV13或安慰剂。
  • 在139例发生主要终点疫苗型社区获得性肺炎的受试者中,通过医疗记录核实免疫接种时糖尿病、心脏疾病、呼吸系统疾病、肝脏疾病、无脾和吸烟情况。
  • 在40,427名受试者中,还基于国际初级保健分类(ICPC)编码确定糖尿病和呼吸系统疾病的存在。

主要发现

  • 在139例发生疫苗型社区获得性肺炎的受试者中,糖尿病引起显著效应修饰(p值0.002),有糖尿病者VE为89.5%(95%CI 65.5-96.8),无糖尿病者VE为24.7%(95%CI -10.4至48.7)。
  • 在40,427名基于ICPC分类确定有无糖尿病的受试者中,发现可比效应修饰(p值0.020),有糖尿病者VE为85.6%(95%CI 36.7-96.7),无糖尿病者VE为7.0%(95%CI -58.5至45.5)。
  • 呼吸系统疾病的效应修饰无统计学显著性,尽管两项分析中有呼吸系统疾病者的VE点估计均较低。
  • 按心脏疾病、吸烟和存在任何合并症分层,无效应修饰证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The 13-valent pneumococcal conjugate-vaccine (PCV13) was effective in preventing vaccine-type Community-Acquired Pneumonia (VT-CAP) and Invasive Pneumococcal Disease (VT-IPD) in elderly subjects, but vaccine efficacy (VE) in patients with comorbidities at time of vaccination is unknown. METHODS: This is a post hoc analysis of the CAPiTA study, a double blind, randomized controlled trial with 84,496 immunocompetent participants aged ⩾65years, receiving PCV13 or placebo vaccination. Presence of diabetes mellitus (DM), heart disease, respiratory disease, liver disease, asplenia, and smoking at the time of immunization was verified on medical records in 139 subjects developing the primary endpoint of VT-CAP. Presence of DM and respiratory disease based on International Classification of Primary Care (ICPC) coding was also determined in 40,427 subjects. FINDINGS: In the 139 subjects developing VT-CAP, DM caused significant effect modification (p-value 0.002), yielding VE of 89.5% (95%CI, 65.5-96.8) and 24.7% (95%CI, -10.4 to 48.7) for those with and without DM, respectively. Comparable effect modification (p-value 0.020) was found in the 40,427 subjects with and without ICPC-based classification of DM with VE of 85.6% (95%CI, 36.7-96.7) and of 7.0% (95%CI, -58.5 to 45.5) respectively. Effect modification through respiratory disease was not statistically significant, although the point estimate of VE was lower for those with respiratory disease in both analyses. There was no evidence of effect modification in subjects stratified by heart disease, smoking, and presence of any comorbidity. CONCLUSIONS: Among immunocompetent elderly, VE of PCV13 was modified by DM with higher VE among subjects with DM. Significant effect modification was not observed for subjects with heart disease, respiratory disease, smoking, or presence of any comorbidity. CAPiTA trial registration number: www.ClinicalTrials.gov; trial number NCT00744263.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Huijts SM, van Werkhoven CH, Bolkenbaas M, et al. Post-hoc analysis of a randomized controlled trial: Diabetes mellitus modifies the efficacy of the 13-valent pneumococcal conjugate vaccine in elderly. Vaccine. 2017. PMID: 28410813. doi:10.1016/j.vaccine.2017.01.071

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。